Cite
APA Citation
Sun, Y., Niu, W., Du, F., Du, C., Li, S., Wang, J., Li, L., Wang, F., Hao, Y., Li, C., & Chi, Y. (2016). safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. Journal of hematology & oncology, 9(1), 1–9. http://access.bl.uk/ark:/81055/vdc_100080855450.0x0000c9